- Dynavax press release ( NASDAQ: DVAX ): Q4 GAAP EPS of $0.45 in-line.
- Revenue of $184.49M (-5.4% Y/Y) beats by $6.11M .
- HEPLISAV-B ® vaccine net product revenue of $126 million, representing 104% growth compared to 2021
- CpG 1018 ® adjuvant vaccine net product revenue of $588 million
- 2023 HEPLISAV-B net product revenue anticipated to be between $165 million and $185 million, representing year-over-year revenue growth of approximately 30-47%
- Increased strength of financial position with year-end cash and investments of $624 million.
- 2023 Outlook: HEPLISAV-B net product revenue between approximately $165 - $185 million
- Research and development expenses between approximately $55 - $70 million
- Selling, general and administrative expenses between approximately $135 - $155 million.
For further details see:
Dynavax GAAP EPS of $0.45 in-line, revenue of $184.49M beats by $6.11M